| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | Clovis Oncology, Inc. | 814,833 | 60,485,054 | 53.20% | ||
| 2 | FIVE PRIME THERAPEUTICS INC | 1,092,152 | 24,955,673 | 21.95% | ||
| 3 | Achaogen, Inc. | 1,281,152 | 12,504,044 | 11.00% | ||
| 4 | CymaBay Therapeutics, Inc. | 1,048,601 | 7,256,319 | 6.38% | ||
| 5 | INOGEN INC | 155,284 | 4,967,535 | 4.37% | ||
| 6 | KYTHERA BIOPHARMACEUTICALS I | 70,376 | 3,529,356 | 3.10% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001104659-15-029755, filed 2015.04.23).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
